CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.
Tang, Kevin Charles
Anderson, Nicole M.
Roderick, Justine E.
Kelliher, Michelle A.
Seldin, David C.
MetadataShow full item record
CitationHaiwei Lian, Dun Li, Yun Zhou, Esther Landesman-Bollag, Guanglan Zhang, Nicole M. Anderson, Kevin Charles Tang, Justine E. Roderick, Michelle A. Kelliher, David C. Seldin, Hui Fu, Hui Feng. 2017. "CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.." Haematologica, Volume 102, Issue 1, pp. e17 - e21.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer of developing thymocytes, and remains fatal in 20% of pediatric and 50% of adult patients.1,2 Frequent application of multi-agent cytotoxic drugs leads to disease relapse and high toxicities, underscoring the need for targeted therapies. The suppression of aberrant NOTCH1 signaling in T-ALL cells by gamma secretase inhibitors (GSIs) has been met with much enthusiasm; however, the gastrointestinal toxicities and drug resistance of GSIs restrain their clinical applications.3 The proto-oncogene MYC is a transcriptional target of NOTCH1 and a dominant driver of T-ALL pathogenesis.3 Targeting MYC-mediated transcriptional programs through BET bromodomain inhibitor JQ1 exhibits anti-leukemic efficacy in vitro and in vivo.4 However, global repression of transcription is predicted to cause toxicities. Identification of drug(s) synergizing with JQ1 to kill T-ALL cells may enhance the efficacy while reducing toxicities. Protein kinase CK2 is a tetrameric serine-threonine kinase composed of two catalytic (α or α′) and regulatory (β) subunits that can phosphorylate NOTCH1.5 CK2 inhibition by CX-4945, a potent and specific inhibitor in clinical trials for treating breast cancer and multiple myeloma, significantly reduces growth and survival of human T-ALL cells,6 and down-regulates NOTCH1 in lung cancer cells.7 However, it remains unclear whether the cytotoxic effect of CX-4945 on T-ALL cells is associated with repression of NOTCH1 signaling. Here we show that CK2 inhibition by CX-4945 destabilizes NOTCH1 and synergizes with JQ1 to induce apoptosis in human T-ALL cells, implicating an alternative strategy to target NOTCH1 signaling in refractory/relapsed T-ALL.
Obtained from the Haematologica Journal website http://www.haematologica.org